Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients
NCT01398644 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2013-12-04
Summary
Hereditary hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload. Phlebotomy is currently the standard therapy. More recently Therapeutic Erythrocytapheresis (TE) has become a new therapeutic modality, which potentially offers a more efficient method to remove iron overload with fewer procedures.In the proposed clinical trial the investigators will examine whether TE can keep the ferritin levels in patients requiring maintenance therapy below 50 microg/L, with minimally half the number of treatment procedures when compared to current standard therapy by P.
Conditions
- Hereditary Hemochromatosis
Interventions
- OTHER
-
Phlebotomy and erythrocytapheresis
Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
Sponsors & Collaborators
-
Maastricht University Medical Center
collaborator OTHER -
Atrium Medical Center
collaborator OTHER -
Radboud University Medical Center
collaborator OTHER -
Orbis Medical Centre
collaborator OTHER -
Sanquin Research & Blood Bank Divisions
lead OTHER
Principal Investigators
-
Eva Rombout, MD · Sanquin Blood Supply
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2013-12-31
- Completion
- 2013-12-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.
NCT05742035 ·Status: UNKNOWN ·Phase: NA
-
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
NCT03203850 ·Status: TERMINATED ·Phase: PHASE2
-
Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?
NCT01631708 ·Status: COMPLETED ·Phase: NA
-
Statistical Basis for Hemochromatosis Screening
NCT00005559 ·Status: COMPLETED
-
Effects of Transfusion of Older Stored Red Cells
NCT01534676 ·Status: TERMINATED ·Phase: NA
-
Cardiac Function in Patients With Hereditary Hemochromatosis
NCT00068159 ·Status: COMPLETED
-
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
NCT00171301 ·Status: COMPLETED ·Phase: PHASE4
-
Hemochromatosis--Genetic Prevalence and Penetrance
NCT00006312 ·Status: COMPLETED
-
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
NCT00395629 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
NCT01892644 ·Status: WITHDRAWN ·Phase: PHASE2
-
PTG-300 in Subjects With Hereditary Hemochromatosis
NCT04202965 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000595 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Therapeutic Phlebotomies on the Triglycerides Concentration in Patients With Hypertriglyceridemia and Hyperferritinemia
NCT02526121 ·Status: COMPLETED ·Phase: NA
-
Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis
NCT04779593 ·Status: RECRUITING ·Phase: NA
-
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
NCT00171210 ·Status: COMPLETED ·Phase: PHASE3
-
Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia Patients
NCT07055503 ·Status: ENROLLING_BY_INVITATION
-
Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter
NCT00481221 ·Status: UNKNOWN
-
Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients
NCT03992001 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload
NCT05440487 ·Status: COMPLETED
-
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
NCT01671111 ·Status: TERMINATED ·Phase: PHASE2
-
Plasmapheresis: a Multi-modal Approach
NCT05815615 ·Status: COMPLETED ·Phase: NA
-
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
NCT00000588 ·Status: COMPLETED ·Phase: PHASE2
-
Deferoxamine for the Treatment of Hemochromatosis
NCT00001203 ·Status: COMPLETED
-
HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
NCT02435901 ·Status: COMPLETED ·Phase: PHASE1/PHASE2